SPRINT Share Price | Sprint Bioscience AB Stock Analysis & Recommendation

Mojo Score Change: Sprint Bioscience AB has changed its score on 15 Jun 2026. Click here to unlock latest mojo score!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Compare Sprint Bioscience AB with Similar Stocks

Ascelia Pharma AB Isofol Medical AB Iconovo AB

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a growth in Operating Profit of 134.9%, the company declared Very Positive results in Mar 26

The company has declared positive results for the last 2 consecutive quarters
OPERATING CASH FLOW(Y) Highest at SEK 69.76 MM
NET SALES(HY) Higher at SEK 133.91 MM
NET PROFIT(HY) Higher at SEK 100.28 MM

With ROE of 76.97%, it has a very attractive valuation with a 1.89 Price to Book Value

Market Beating performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 371 Million (Micro Cap)

P/E

2.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.06

Return on Equity

76.97%

Price to Book

3.12

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2026)

Net Profit:

-13 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

112.8%

6 Months

210.73%

1 Year

801.61%

2 Years

214.87%

3 Years

767.97%

4 Years

70.57%

5 Years

-36.36%

Sprint Bioscience AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

58.16%

EBIT Growth (5y)

34.70%

EBIT to Interest (avg)

-23.27

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-5.17

Sales to Capital Employed (avg)

5.26

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

7.10%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.89

EV to EBIT

1.01

EV to EBITDA

1.00

EV to Capital Employed

-13.03

EV to Sales

0.59

PEG Ratio

0.01

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

76.97%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is -100.00% vs -21.23% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is -130.36% vs -80.65% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "14.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.10",
          "val2": "-4.50",
          "chgp": "-213.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-12.90",
          "val2": "-5.60",
          "chgp": "-130.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-335.20%",
          "chgp": "33.52%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 154.88% vs 29.90% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 601.09% vs -4,475.00% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "167.20",
          "val2": "65.60",
          "chgp": "154.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "98.40",
          "val2": "-19.00",
          "chgp": "617.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "91.70",
          "val2": "-18.30",
          "chgp": "601.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "582.20%",
          "val2": "-303.70%",
          "chgp": "88.59%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

0.00

14.10

-100.00%

Operating Profit (PBDIT) excl Other Income

-14.10

-4.50

-213.33%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-12.90

-5.60

-130.36%

Operating Profit Margin (Excl OI)

0.00%

-335.20%

33.52%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is -100.00% vs -21.23% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is -130.36% vs -80.65% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

167.20

65.60

154.88%

Operating Profit (PBDIT) excl Other Income

98.40

-19.00

617.89%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

91.70

-18.30

601.09%

Operating Profit Margin (Excl OI)

582.20%

-303.70%

88.59%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 154.88% vs 29.90% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 601.09% vs -4,475.00% in Dec 2024

All Annual Results

Company CV

About Sprint Bioscience AB

Sprint Bioscience AB

Pharmaceuticals & Biotechnology

Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Company’s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.

Company Coordinates

Company Details

Novum, Halsovagen 7, Floor 8, elevator A , HUDDINGE None : 141 57

Tel: 46 8 4114455

https://www.sprintbioscience.com/

Registrar Details